Relmada Therapeutics Issues 600,000 Options to CFO in Latest Form 4

Rhea-AI Filing Summary

Relmada Therapeutics, Inc. (RLMD) – Form 4 insider filing: The company’s Chief Financial Officer, Maged Shenouda, was granted stock options for 600,000 common shares on 06/26/2025. The options carry an exercise price of $0.67 per share and will vest in 16 equal quarterly installments beginning 09/26/2025, fully vesting by 06/26/2035. Following the grant, Shenouda beneficially owns 600,000 derivative securities, reported as direct ownership. No shares were purchased or sold in the open market; this filing records an equity incentive award, aligning executive compensation with future shareholder value.

Positive

• Long-term vesting schedule promotes executive retention and aligns CFO incentives with shareholder value.
• No insider selling; the filing reflects an option grant rather than disposal of existing shares.

Negative

• Potential dilution if all 600,000 options are exercised, increasing outstanding share count.
• Strike price of $0.67 may signal low current valuation, highlighting execution risk for value realization.

Insights

Corporate Governance Analyst

TL;DR: Routine option grant; modest positive alignment, minimal short-term impact.

The 600,000-share option award strengthens management retention and incentive alignment, especially given RLMD’s depressed $0.67 strike price. However, the grant represents potential dilution only if exercised and is standard for a C-suite hire/retention, so market impact should be neutral to mildly positive. No immediate cash outflow or insider selling occurred, and vesting over four years promotes long-term commitment. Investors should monitor total option overhang but need not expect short-term price movement based solely on this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Shenouda Maged

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	600,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 600,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shenouda Maged

(Last) (First) (Middle)

C/O RELMADA THERAPEUTICS, INC.

2222 PONCE DE LEON BLVD, 3RD FLOOR

(Street)

CORAL GABLES, FL 33134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RELMADA THERAPEUTICS, INC. [ RLMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.67	06/26/2025		A		600,000		09/26/2025(1)	06/26/2035	Common Stock	600,000	$0	600,000	D

Explanation of Responses:

1. The options vest in 16 equal quarterly installments commencing on September 26, 2025.

	/s/ Maged Shenouda	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider involved in RLMD's latest Form 4 filing?

The filing involves Maged Shenouda, Chief Financial Officer of Relmada Therapeutics.

How many options were granted to RLMD's CFO?

He received 600,000 stock options for Relmada’s common stock.

What is the exercise price of the newly granted RLMD options?

The options have an exercise price of $0.67 per share.

When do the RLMD options vest?

They vest in 16 equal quarterly installments starting 09/26/2025 and fully vest by 06/26/2035.

Did RLMD's CFO buy or sell any shares in this filing?

No. The Form 4 only reports an option grant; there was no purchase or sale of common shares.